Source:http://linkedlifedata.com/resource/pubmed/id/18178903
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2008-3-18
|
pubmed:abstractText |
Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) is a major protein kinase that is capable of regulating the activities of many ion channels and receptors. In the present study, the role of CaMKII in the complete Freund's adjuvant (CFA)-induced inflammatory pain was investigated. Intraplantarly injected CFA was found to induce spinal activity of CaMKII (phosphorylated CaMKII), which was blocked by KN93 [[2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine)], a CaMKII inhibitor. Pretreatment with KN93 (i.t.) dose-dependently prevented the development of CFA-induced thermal hyperalgesia and mechanical allodynia. Acute treatment with KN93 (i.t.) also dose-dependently reversed CFA-induced thermal hyperalgesia and mechanical allodynia. The action of KN93 started in 30 min and lasted for at least 2 to 4 h. KN92 (45 nmol i.t.) [2-[N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine], an inactive analog of KN93, showed no effect on CFA-induced CaMKII activation, allodynia, or hyperalgesia. Furthermore, our previous studies identified trifluoperazine, a clinically used antipsychotic drug, to be a potent CaMKII inhibitor. Inhibition of CaMKII activity by trifluoperazine was confirmed in the study. In addition, trifluoperazine (i.p.) dose-dependently reversed CFA-induced mechanical allodynia and thermal hyperalgesia. The drug was also effectively when given orally. In conclusion, our findings support a critical role of CaMKII in inflammatory pain. Blocking CaMKII or CaMKII-mediated signaling may offer a novel therapeutic target for the treatment of chronic pain.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Benzylamines,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium-Calmodulin-Dependent...,
http://linkedlifedata.com/resource/pubmed/chemical/Freund's Adjuvant,
http://linkedlifedata.com/resource/pubmed/chemical/KN 93,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1521-0103
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
325
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
267-75
|
pubmed:meshHeading |
pubmed-meshheading:18178903-Animals,
pubmed-meshheading:18178903-Benzylamines,
pubmed-meshheading:18178903-Calcium-Calmodulin-Dependent Protein Kinase Type 2,
pubmed-meshheading:18178903-Dose-Response Relationship, Drug,
pubmed-meshheading:18178903-Freund's Adjuvant,
pubmed-meshheading:18178903-Hyperalgesia,
pubmed-meshheading:18178903-Inflammation,
pubmed-meshheading:18178903-Mice,
pubmed-meshheading:18178903-Mice, Inbred ICR,
pubmed-meshheading:18178903-Pain,
pubmed-meshheading:18178903-Remission Induction,
pubmed-meshheading:18178903-Spine,
pubmed-meshheading:18178903-Sulfonamides
|
pubmed:year |
2008
|
pubmed:articleTitle |
Reversal of chronic inflammatory pain by acute inhibition of Ca2+/calmodulin-dependent protein kinase II.
|
pubmed:affiliation |
Department of Biopharmaceutical Sciences, University of Illinois, 833 South Woods Street, Chicago, IL 60612, USA.
|
pubmed:publicationType |
Journal Article
|